SCHEMBL30112428

SCHEMBL30112428

COC(=O)CC1CCN(c2ccc(-c3ccc(OCc4ccccc4)nc3OCc3ccccc3)cn2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 7/20 0.43
KCNH2 Q12809 4/20 0.43
CHRM4 P08173 1/20 0.41
IDH1 O75874 1/20 0.40
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
TSHR P16473 1/20 0.39
RAB9A P51151 1/20 0.39
JAK3 P52333 1/20 0.39
LTA4H P09960 1/20 0.39
DEGS1 O15121 1/20 0.39
PDE10A Q9Y233 1/20 0.38
ADORA2A P29274 1/20 0.38
CKS1B P61024 2/20 0.38
SKP1 P63208 2/20 0.38
SKP2 Q13309 2/20 0.38
CETP P11597 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29197741 1.00 DGAT1 (0.43) DGAT1KCNH2CHRM4IDH1LMNA
SCHEMBL30442115 0.95 IDH1 (0.46) DGAT1KCNH2CHRM4IDH1LMNA
SCHEMBL25504065 0.95 IDH1 (0.46) DGAT1KCNH2CHRM4IDH1LMNA
SCHEMBL24881518 0.91 DGAT1 (0.48) DGAT1KCNH2IDH1LMNASMN1; SMN2
SCHEMBL24670866 0.91 CKS1B (0.42) DGAT1KCNH2CHRM4IDH1CKS1B
SCHEMBL30888783 0.91 CKS1B (0.42) DGAT1KCNH2CHRM4IDH1CKS1B
SCHEMBL30066533 0.88 DGAT1 (0.41) DGAT1KCNH2CHRM4IDH1JAK3
SCHEMBL29872807 0.86 PRMT5 (0.41) DGAT1KCNH2PDE10APRMT5
SCHEMBL23459570 0.86 PRMT5 (0.41) DGAT1KCNH2PDE10APRMT5
SCHEMBL25190189 0.86 IDH1 (0.53) DGAT1KCNH2IDH1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240343733-A1 COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS C4 THERAPEUTICS, INC. 2024-10-17 US disclosed
EP-4367113-A1 COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS Biogen MA Inc. (US) 2024-05-15 EP disclosed
WO-2023283610-A1 COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS BIOGEN MA INC. (US) 2023-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240343733-A1 COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS IRAK4, IRAK2, IRAK1 DGAT1 3568/4885KCNH2 4828/4885CHRM4 3667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.